AbbVie (NYSE:ABBV – Get Free Report) issued an update on its fourth quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 3.830-3.870 for the period, compared to the consensus estimate of 3.890. The company issued revenue guidance of $18.4 billion, compared to the consensus revenue estimate of $18.3 billion. AbbVie also updated its FY 2026 guidance to 13.950-13.990 EPS.
Analyst Ratings Changes
ABBV has been the subject of a number of recent research reports. Cantor Fitzgerald lifted their price objective on AbbVie from $290.00 to $325.00 and gave the company an “overweight” rating in a research note on Monday. Rothschild & Co Redburn upped their target price on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Citigroup raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Wells Fargo & Company lifted their price target on AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $296.88.
View Our Latest Analysis on ABBV
AbbVie Stock Down 1.0%
AbbVie stock opened at $285.88 on Wednesday. AbbVie has a 52-week low of $190.75 and a 52-week high of $298.74. The firm has a market capitalization of $505.09 billion, a price-to-earnings ratio of 49.20, a PEG ratio of 1.31 and a beta of 0.20. The company has a fifty day simple moving average of $270.23 and a 200-day simple moving average of $237.89.
AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.86 earnings per share. On average, research analysts anticipate that AbbVie will post 14.00 EPS for the current fiscal year.
AbbVie Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $1.82 dividend. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Friday, January 15th. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is currently 119.10%.
Insiders Place Their Bets
In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.
AbbVie News Roundup
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie signed a global license deal for Nxera Pharma’s investigational oral EP4 agonist for inflammatory bowel disease. The agreement includes $100 million upfront, up to $1.37 billion in contingent development and commercial milestones, and royalties. It adds potential pipeline value, though payments beyond the upfront fee depend on development and commercial success. Nxera Pharma license agreement with AbbVie
- Positive Sentiment: Several analysts raised their price targets and maintained positive ratings following AbbVie’s recent results, adding support to the view that earnings growth and its newer medicines can sustain momentum. Morgan Stanley raises AbbVie price target
- Positive Sentiment: AbbVie raised its 2026 outlook, with full-year revenue guidance of $67.8 billion above the cited consensus of $67.6 billion. Recent quarterly results also showed revenue growth, while Skyrizi and Rinvoq are helping offset Humira’s decline. AbbVie Q3 results and growth drivers
- Neutral Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million. The expansion supports research capacity over time, but does not indicate an immediate revenue contribution. AbbVie expands Oxford R&D facility
- Negative Sentiment: AbbVie is abandoning a Phase 2 solid-tumor drug program after seeing “limited benefit,” a setback for its oncology pipeline. Fourth-quarter EPS guidance of $3.83–$3.87 also falls short of the cited $3.89 consensus, despite revenue guidance slightly above estimates. AbbVie discontinues Phase 2 solid-tumor drug
About AbbVie
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Read More
- Five stocks we like better than AbbVie
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
